CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Mometasone furoate

Last Updated: November 10, 2011
Result type: Reports
Project Number: SR0258-000
Product Line: Reimbursement Review

Generic Name: Mometasone furoate

Brand Name: ASMANEX

Manufacturer: Merck Canada Inc.

Therapeutic Area: Asthma

Indications: Asthma, (Bronchial) Prophylactic management of steroid responsive

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 16, 2012

Recommendation Type: List